Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial
Highlights
The NIVOLEP trial represents a significant advancement in the multimodal treatment of hepatocellular carcinoma. Neoadjuvant and adjuvant nivolumab combined with irreversible electroporation achieved a one-year local recurrence-free survival rate of 70.6% in patients with BCLC A HCC at high risk of recurrence. Pathological response rates reached 26.3% following neoadjuvant immunotherapy, with RNA sequencing confirming robust immune activation within the tumor microenvironment. The combination approach demonstrates acceptable safety with grade 3-4 adverse events occurring in only 2 patients, though one treatment-related mortality was observed. These findings suggest that perioperative immunotherapy may enhance the efficacy of ablation-based treatment strategies in liver cancer.
Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.